Adriana Barrichello - Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 89 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Federica Pecci,Rohit Thummalapalli, Stephanie L Alden,Biagio Ricciuti, Joao V Alessi,Arielle Elkrief,Hira Rizvi, Xinan Wang, Mark Jeng,Jacklynn V Egger, Victor R Vaz,Adriana Barrichello,Giuseppe Lamberti,Alessandro Di Federico, Valentina Santo, Guilherme Rossato de Almeida,Malini Gandhi, Phoebe Clark,Mizuki Nishino, Bruce E Johnson,Matthew Hellmann,Adam J Schoenfeld, Mark M Awad

Clinical cancer research an official journal of the American Association for Cancer Research（2025）

Cited0Views0WOSBibtex

Supplementary Figure 20 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 13 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure 10 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 4 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 24 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 14 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 17 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 11 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Supplementary Methods from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn